{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T18:53:49Z","timestamp":1784573629782,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"am","delay-in-days":368,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.xphs.2025.01.024","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T21:36:21Z","timestamp":1738272981000},"page":"1615-1624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A spleen-targeted vaccine for SARS-CoV-2 \u2014 Inducting neutralizing antibodies in mice"],"prefix":"10.1016","volume":"114","author":[{"given":"Taro","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshino","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-2239","authenticated-orcid":false,"given":"Haruka","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6247-7574","authenticated-orcid":false,"given":"Hidenori","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-6465","authenticated-orcid":false,"given":"Tatsuhiro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2025.01.024_bib0001","unstructured":"COVID-19 epidemiological update available at: https:\/\/www.who.int\/publications\/m\/item\/covid-19-epidemiological-update\u201419-january-2024."},{"key":"10.1016\/j.xphs.2025.01.024_bib0002","article-title":"Prognostic factors for COVID-19 pneumonia progression to severe symptoms based on earlier clinical features: a retrospective analysis","volume":"7","author":"Huang","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.xphs.2025.01.024_bib0003","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","article-title":"Long COVID: major findings, mechanisms and recommendations","volume":"21","author":"Davis","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"11","key":"10.1016\/j.xphs.2025.01.024_bib0004","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.xphs.2025.01.024_bib0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.xphs.2025.01.024_bib0006","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"10262","key":"10.1016\/j.xphs.2025.01.024_bib0007","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0140-6736(20)32137-1","article-title":"SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates","volume":"396","author":"Poland","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.xphs.2025.01.024_bib0008","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacol Sin"},{"issue":"7830","key":"10.1016\/j.xphs.2025.01.024_bib0009","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.xphs.2025.01.024_bib0010","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.cell.2020.11.032","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xphs.2025.01.024_bib0011","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.addr.2019.09.005","article-title":"Physical and chemical profiles of nanoparticles for lymphatic targeting","volume":"151-152","author":"Ke","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2025.01.024_bib0012","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.copbio.2020.06.015","article-title":"Engineering nanoparticulate vaccines for enhancing antigen cross-presentation","volume":"66","author":"Du","year":"2020","journal-title":"Curr Opin Biotechnol"},{"issue":"1","key":"10.1016\/j.xphs.2025.01.024_bib0013","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1038\/s41467-021-27493-0","article-title":"An ionizable lipid toolbox for RNA delivery","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.xphs.2025.01.024_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2025.01.024_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.954936","article-title":"Role of B cells as antigen presenting cells","volume":"13","author":"Rastogi","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.xphs.2025.01.024_bib0016","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1248\/cpb.c22-00047","article-title":"Development of an antigen delivery system for a B cell-targeted vaccine as an alternative to dendritic cell-targeted vaccines","volume":"70","author":"Shimizu","year":"2022","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"2","key":"10.1016\/j.xphs.2025.01.024_bib0017","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nri3383","article-title":"Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes","volume":"13","author":"Cerutti","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.xphs.2025.01.024_bib0018","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.imbio.2012.08.274","article-title":"Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon","volume":"218","author":"Shimizu","year":"2013","journal-title":"Immunobiology"},{"issue":"10","key":"10.1016\/j.xphs.2025.01.024_bib0019","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.4049\/jimmunol.1701351","article-title":"A novel platform for cancer vaccines: antigen-selective delivery to splenic marginal zone B cells via repeated injections of PEGylated liposomes","volume":"201","author":"Shimizu","year":"2018","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.xphs.2025.01.024_bib0020","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.vaccine.2021.01.008","article-title":"Lymphoid follicle antigen (Ag) delivery and enhanced rodent humoral immune responses mediated by Ag-containing PEGylated liposomes","volume":"39","author":"Shimizu","year":"2021","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.xphs.2025.01.024_bib0021","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1248\/bpb.b22-00222","article-title":"Development of a nanocarrier-based splenic B cell-targeting system for loading antigens in Vitro","volume":"45","author":"Kawaguchi","year":"2022","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"10.1016\/j.xphs.2025.01.024_bib0022","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/(SICI)1521-4141(199901)29:01<345::AID-IMMU345>3.0.CO;2-K","article-title":"Chronic intravenous injections of antigen induce and maintain tolerance in T cell receptor-transgenic mice","volume":"29","author":"Bercovici","year":"1999","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.xphs.2025.01.024_bib0023","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.coi.2005.04.009","article-title":"Marginal zone B cells in lymphocyte activation and regulation","volume":"17","author":"Lopes-Carvalho","year":"2005","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"10.1016\/j.xphs.2025.01.024_bib0024","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1128\/IAI.00422-07","article-title":"Marginal zone B-cell depletion impairs murine host defense against Borrelia burgdorferi infection","volume":"75","author":"Belperron","year":"2007","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.xphs.2025.01.024_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114426","article-title":"Splenic marginal zone B cells restrict mycobacterium tuberculosis infection by shaping the cytokine pattern and cell-mediated immunity","volume":"43","author":"Tsai","year":"2024","journal-title":"Cell Rep"},{"issue":"13","key":"10.1016\/j.xphs.2025.01.024_bib0026","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1286-4579(02)00012-6","article-title":"Immune downregulation leads to upregulation of an antiviral response: a lesson from the hepatitis B virus","volume":"4","author":"Ilan","year":"2002","journal-title":"Microbes Infect"},{"issue":"9","key":"10.1016\/j.xphs.2025.01.024_bib0027","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.4049\/jimmunol.1600965","article-title":"Low antigen dose in adjuvant-based vaccination selectively induces CD4 T cells with enhanced functional avidity and protective efficacy","volume":"198","author":"Billeskov","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.xphs.2025.01.024_bib0028","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fimmu.2017.00301","article-title":"Immunoregulatory role of NK cells in tissue inflammation and regeneration","volume":"8","author":"Tosello-Trampont","year":"2017","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.xphs.2025.01.024_bib0029","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1128\/CMR.16.4.597-621.2003","article-title":"Infections in patients with inherited defects in phagocytic function","volume":"16","author":"Andrews","year":"2003","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.xphs.2025.01.024_bib0030","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jconrel.2006.08.001","article-title":"Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes","volume":"115","author":"Ishida","year":"2006","journal-title":"J Control Release"},{"issue":"33","key":"10.1016\/j.xphs.2025.01.024_bib0031","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1016\/j.vaccine.2017.06.003","article-title":"The complexity and cost of vaccine manufacturing - an overview","volume":"35","author":"Plotkin","year":"2017","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.xphs.2025.01.024_bib0032","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41565-018-0273-1","article-title":"Roadmap and strategy for overcoming infusion reactions to nanomedicines","volume":"13","author":"Szebeni","year":"2018","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"10.1016\/j.xphs.2025.01.024_bib0033","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.xphs.2025.01.024_bib0034","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1172\/JCI81083","article-title":"Beyond antigens and adjuvants: formulating future vaccines","volume":"126","author":"Moyer","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.xphs.2025.01.024_bib0035","article-title":"Unglycosylated soluble SARS-CoV-2 receptor binding domain (RBD) produced in E. coli combined with the army liposomal formulation containing QS21 (ALFQ) elicits neutralizing antibodies against mismatched variants","volume":"11","author":"Balasubramaniyam","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"10.1016\/j.xphs.2025.01.024_bib0036","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1021\/acscentsci.0c01056","article-title":"Beyond shielding: the roles of glycans in the SARS-CoV-2 spike protein","volume":"6","author":"Casalino","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.xphs.2025.01.024_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.737973","article-title":"Altering the immunogenicity of hemagglutinin immunogens by hyperglycosylation and disulfide stabilization","volume":"12","author":"Thornlow","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2025.01.024_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1118523","article-title":"Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants","volume":"14","author":"Carnell","year":"2023","journal-title":"Front Immunol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925000450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925000450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T01:40:25Z","timestamp":1741052425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925000450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0022354925000450"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.01.024","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A spleen-targeted vaccine for SARS-CoV-2 \u2014 Inducting neutralizing antibodies in mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}